StreetInsider.com News Articles

Form 6-K INTERMAP TECHNOLOGIES For: Oct 16

Fri, 16 Oct 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20261016/27197087.html

Form 6-K INTERMAP TECHNOLOGIES For: Oct 07

Thu, 08 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261008/27162941.html

Intermap acquires PCI Geomatics for $7.7M, targets $12-15M revenue

Wed, 07 Oct 2026 17:30:15 -0400

Intermap Technologies (TSX: IMP; OTCQB: ITMSF) completed its acquisition of PCI Geomatics Group Inc., which operates as CATALYST, on October 7, 2026, using $7.7 million in cash to finalize the transaction.

The deal followed shareholder approval on September 25, 2026, and a final order from the Ontario Superior Court of Justice dated September 28, 2026. Intermap acquired all outstanding PCI shares it did not already own under the Canada Business Corporations Act.

According to the company, the acquisition is expected to double Intermap's recurring revenue. PCI brings more than 30,000 installed software licenses across over 150 countries, along with optical image processing

Intermap Completes Acquisition of PCI Geomatics

Wed, 07 Oct 2026 17:30:00 -0400

Accelerates Intermap’s technology roadmap into distributed edge processing and microservices, extending proven and secure AI/ML analytics across thousands of autonomous geospatial workflows

Doubles recurring revenue, opening new commercialization pathways for Intermap’s AI/ML-driven image processing and downstream products, including solution enhancements for 30,000+ existing licenses in the commercial space market

Speeds delivery of decision-ready intelligence throughout Intermap’s asset-light platform, integrating our AI/ML analytics, large-scale, real-time, multi-domain 3D data with value-added software and APIs spanning complete-spectrum remote sensing on Earth, in the air, under sea and in space

Introducing 2027 commercial revenue guidance of

Intermap Completes Acquisition of PCI Geomatics

Wed, 07 Oct 2026 17:30:00 -0400

Accelerates Intermap’s technology roadmap into distributed edge processing and microservices, extending proven and secure AI/ML analytics across thousands of autonomous geospatial workflows

Doubles recurring revenue, opening new commercialization pathways for Intermap’s AI/ML-driven image processing and downstream products, including solution enhancements for 30,000+ existing licenses in the commercial space market

Speeds delivery of decision-ready intelligence throughout Intermap’s asset-light platform, integrating our AI/ML analytics, large-scale, real-time, multi-domain 3D data with value-added software and APIs spanning complete-spectrum remote sensing on Earth, in the air, under sea and in space

Introducing 2027 commercial revenue guidance of

Form 6-K INTERMAP TECHNOLOGIES For: Sep 28

Mon, 28 Sep 2026 07:45:00 -0400
si-local-file:///var/storage/secattach/20260928/27110143.html

Form 6-K INTERMAP TECHNOLOGIES For: Sep 28

Mon, 28 Sep 2026 07:45:00 -0400
si-local-file:///var/storage/secattach/20260928/27110143.html

Form 6-K INTERMAP TECHNOLOGIES For: Sep 21

Mon, 21 Sep 2026 07:45:00 -0400
si-local-file:///var/storage/secattach/20260921/27083059.html

Form 6-K INTERMAP TECHNOLOGIES For: Sep 21

Mon, 21 Sep 2026 07:45:00 -0400
si-local-file:///var/storage/secattach/20260921/27083059.html

Intermap Expands Global Insurance Business with Three-Year Fairfax Financial Subscription

Mon, 21 Sep 2026 07:30:00 -0400

Integrated flood risk and property valuation solution advances recurring revenue strategy and supports expansion across markets
DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced a three-year subscription agreement with Colonnade Insurance S.A. (“Colonnade”) for an integrated flood risk and property valuation solution. Colonnade is a Luxembourg-based non-life insurance company owned by Fairfax Financial Holdings, a Canadian international financial services holding company listed on the Toronto Stock Exchange. Through its subsidiaries, Fairfax is engaged in

Intermap Expands Global Insurance Business with Three-Year Fairfax Financial Subscription

Mon, 21 Sep 2026 07:30:00 -0400

Integrated flood risk and property valuation solution advances recurring revenue strategy and supports expansion across markets
DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced a three-year subscription agreement with Colonnade Insurance S.A. (“Colonnade”) for an integrated flood risk and property valuation solution. Colonnade is a Luxembourg-based non-life insurance company owned by Fairfax Financial Holdings, a Canadian international financial services holding company listed on the Toronto Stock Exchange. Through its subsidiaries, Fairfax is engaged in

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica to host Capital Markets Day in Stockholm on September 9

Tue, 25 Aug 2026 02:25:00 -0400

VADUZ, Liechtenstein, Aug. 25, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, today announced that it will host a Capital Markets Day on September 9, 14:00-16:30 CEST in Stockholm.

"With FDA approval now secured, we are moving full speed ahead on our U.S. launch. This is a defining moment for Implantica and a huge opportunity to bring

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data

Implantica publishes Interim Report January - June 2026 (Q2)

Fri, 21 Aug 2026 02:24:00 -0400

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success

Significant events in the second quarter of 2026
RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets
Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2%
Clinical, health-economic and reimbursement evidence further strengthened, including new Italian cost-effectiveness data